重新审视化疗在晚期前列腺癌治疗中的地位  

Status of chemotherapy in the treatment of advanced prostate cancer

作　　者：周爱萍[1] 马建辉[1] 

机构地区：[1]北京协和医学院中国医学科学院肿瘤医院,北京100021

出　　处：《中国新药杂志》2014年第17期2026-2029,共4页Chinese Journal of New Drugs

摘　　要：1996年,美国FDA批准米托蒽醌用于去势抗拒的前列腺癌(CRPC)的治疗,但其对延长总生存无明显益处。2004年,多西他赛联合泼尼松被证实可延长CRPC患者的生存,但目前CRPC仍面临治疗手段单一和疗效有限的困境。近年来临床研究证实新的内分泌药物在晚期前列腺癌治疗中有着不可替代的作用。2014年ASCO会议上报告的抗雄激素治疗联合多西他赛提高晚期前列腺癌患者的生存(激素敏感型),更促使我们不得不从新的角度审视化疗在晚期前列腺癌治疗中的作用和地位。本文就一些相关问题进行了讨论和阐述。In 1996, mitoxantrone was approved by FDA for the treatment of castration resistance prostate cancer （CRPC） , but there were no obvious benefit to extend the total survival. In 2004, docetaxel combined with prednisone were confirmed to prolong the survival of patients with CRPC. However, the patients of CRPC still faced the limited treatment and curative effect. In recent years, clinical studies have confirmed that the new endocrine drugs play an irreplaceable role in advanced prostate cancer therapy, and the status of chemotherapy has been chal- lenged. A report was given about that androgen deprivation therapy combined with docetaxel could improve the sur- vival of patients with advanced prostate cancer （sensitive to hormone） in 2014 ASCO meeting. We have to pay more attention to look for new points about the chemotherapy in the treatment of advanced prostate cancer. In this paper, some related problems were discussed and expounded.

关 键 词：化疗 晚期前列腺癌 内分泌药物 

分 类 号：R979.1[医药卫生—药品]